NASDAQ: ALT · Life Sciences · 8 alerts · CIK 1326190
Share price
$1.56Close, Nov 16
Market cap
$304M
Shares outstanding
194.59MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Altimmune, Inc. filings on SEC EDGAR ↗
Altimmune CFO Gregory L. Weaver Buys $16.2K of Stock
Gregory L. Weaver, CFO, bought 10,000 shares of Altimmune, Inc. at $1.62 a share, worth $16.2K in total on Nov 13, 2026. Shares held after the trade: 73,005 (+15.9%).
Altimmune Director Wayne Pisano Buys $16.4K of Stock
Wayne Pisano, Director, bought 10,000 shares of Altimmune, Inc. at $1.64 a share, worth $16.4K in total on Nov 13, 2026. Shares held after the trade: 58,800 (+20.5%).
Altimmune President and CEO Jerome Benedict Durso Buys $49.7K of Stock
Jerome Benedict Durso, President and CEO, bought 30,700 shares of Altimmune, Inc. at $1.62 a share, worth $49.7K in total on Nov 13, 2026. Shares held after the trade: 93,200 (+49.1%).
Altimmune, Inc. reported a net loss of $77.0 million for the nine months ended September 30, 2026, compared to $60.7 million in the prior year, driven by increased research and development expenses. The company significantly strengthened its balance sheet through public and direct offerings, ending the period with $495.6 million in total assets, including $265.1 million in cash and investments.
Altimmune reported third quarter 2026 financial results and provided a business update on its pemvidutide clinical programs. The company ended the quarter with $480 million in cash and is progressing its Phase 3 PERFORMA trial in MASH and preparing for an End-of-Phase 2 meeting with the FDA for its AUD program in December 2026.
“We continue to make significant progress across all our clinical development programs, as we execute our strategy of building a liver franchise around pemvidutide. Our global PERFORMA Phase 3 trial in MASH is ramping up, and we are very encouraged by the progress to date and the enthusiasm we see from the MASH community.”
Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune
“In AUD, we look forward to engaging with the FDA in an End-of-Phase 2 meeting where we will leverage our strong RECLAIM data to discuss a Phase 3 registrational program. Following the recent AASLD meeting, our conviction in pemvidutide’s potential is stronger than ever, as we focus on delivering meaningful benefit to patients with serious liver diseases.”
Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune
Altimmune $10M Debt Financing with Hercules Capital, Inc.
Altimmune, Inc. has drawn down $10.0 million (Tranche Three) from its existing $125.0 million Loan and Security Agreement with Hercules Capital, Inc. following the achievement of specific clinical and financial milestones. The draw-down extends the interest-only period and amortization date to June 1, 2028, and requires the company to maintain a minimum cash balance equal to 60% of the outstanding principal.
Altimmune appointed Peter Greenleaf and Alex Howarth to its Board of Directors effective November 2, 2026, increasing the board size to eleven. As part of a planned transition, directors John M. Gill, Mitchel Sayare, and Klaus O. Schafer will retire at the 2027 Annual Meeting. The new directors will receive an annual cash retainer of $40,000 and initial stock options for 160,000 shares each.